Surgical Robotics: The Cutting-Edge Frontier in MedTech Innovation

Morgan Stanley is spotlighting the burgeoning surgical robotics sector, identifying two stocks poised for significant growth: Intuitive Surgical (ISRG) and PROCEPT BioRobotics (PRCT). The global surgical robotics market is expected to grow at a compound annual growth rate (CAGR) of 13.7%, reaching $28.54 billion by 2031, driven by increasing chronic disease rates and advancements in medical technology​.

Intuitive Surgical (ISRG): A leader in minimally invasive robotic surgery, Intuitive Surgical recently launched its fifth-generation da Vinci system, featuring over 150 enhancements, including advanced imaging, tremor controls, and ergonomic consoles. Data from 230 studies across 22 countries highlight the system's ability to reduce surgical complications and hospital stays. ISRG’s financials also impress, with Q3 revenues of $2.04 billion (up 17% YoY) and a 20-cent EPS beat on expectations. Analyst Andrew Ranieri notes the company’s potential to expand into new surgical areas, projecting a price target of $650, indicating a 21% upside​.

PROCEPT BioRobotics (PRCT): Specializing in urological health, PROCEPT’s Aquablation therapy offers a robotic, heat-free waterjet solution for benign prostatic hyperplasia (BPH). The FDA recently approved its next-gen HYDROS system, incorporating AI for improved imaging and treatment plans. PROCEPT reported Q3 revenues of $58.37 million (up 66% YoY), and despite posting a loss, its performance beat estimates. Analyst Patrick Wood suggests the company’s potential market penetration could exceed 50% in interventional BPH procedures, targeting a price of $105, implying a 26% upside​.

Both companies highlight the intersection of innovation and investor opportunity in a rapidly expanding field, signaling strong prospects for 2024 and beyond.